ARTICLE | Clinical News
Naltrel: Phase II
February 12, 2001 8:00 AM UTC
DrugAbuse Sciences Inc., Los Altos, Calif. Product: Naltrel Business: Neurological Therapeutic category: Receptor antagonist Target: Opioid receptors Description: Slow release injectable formulation o...